Natural Products Targeting PI3K/AKT in Myocardial Ischemic Reperfusion Injury: A Scoping Review.
Syarifah Aisyah Syed Abd HalimNorhashima Abd RashidChoy Ker WoonNahdia Afiifah Abdul JalilPublished in: Pharmaceuticals (Basel, Switzerland) (2023)
This scoping review aimed to summarize the effects of natural products targeting phosphoinositide-3-kinases/serine/threonine kinase (PI3K/AKT) in myocardial ischemia-reperfusion injury (MIRI). The review details various types of natural compounds such as gypenoside (GP), gypenoside XVII (GP-17), geniposide, berberine, dihydroquercetin (DHQ), and tilianin which identified to reduce MIRI in vitro and in vivo by regulating the PI3K/AKT signaling pathway. In this study, 14 research publications that met the inclusion criteria and exclusion criteria were shortlisted. Following the intervention, we discovered that natural products effectively improved cardiac functions through regulation of antioxidant status, down-regulation of Bax, and up-regulation of Bcl-2 and caspases cleavage. Furthermore, although comparing outcomes can be challenging due to the heterogeneity in the study model, the results we assembled here were consistent, giving us confidence in the intervention's efficacy. We also discussed if MIRI is associated with multiple pathological condition such as oxidative stress, ERS, mitochondrial injury, inflammation, and apoptosis. This brief review provides evidence to support the huge potential of natural products used in the treatment of MIRI due to their various biological activities and drug-like properties.
Keyphrases
- pi k akt
- oxidative stress
- signaling pathway
- cell cycle arrest
- ischemia reperfusion injury
- induced apoptosis
- cell proliferation
- left ventricular
- randomized controlled trial
- epithelial mesenchymal transition
- protein kinase
- metabolic syndrome
- cerebral ischemia
- atrial fibrillation
- type diabetes
- endoplasmic reticulum stress
- acute coronary syndrome
- climate change
- coronary artery disease
- anti inflammatory
- percutaneous coronary intervention
- drug delivery
- dna binding